However, as in the present study, no differences were observed in LVEF values at the end of treatment in the R‐CHOP compared to the R‐COMP group, suggesting that the substitution of conventional doxorubicin by non‐pegylated doxorubicin does not seem to protect against anthracycline‐derived subclinical cardiotoxicity, at least in terms of LVEF decrease in DLBCL patients. The gene discussed is COMP; the disease is diffuse large B-cell lymphoma.